Monitor upcoming clinical trial readouts in 2H 2026 for further validation of paxalisib's efficacy in breast cancer and glioblastoma. The strong cash position reduces the likelihood of near-term dilutive financing, making the stock less sensitive to capital raises in the short term.
Price Chart
Executive Summary
Kazia Therapeutics released an investor presentation highlighting positive clinical data for its lead asset paxalisib, including a complete metabolic response in a stage IV triple-negative breast cancer (TNBC) patient and partial responses in two others. The company also announced a cash runway extending into 2029 and advancement of its preclinical platforms. This update reinforces the company's clinical momentum and financial stability.
Key Facts
- Paxalisib achieved a complete metabolic response in a stage IV TNBC patient under expanded access and two partial responses in an ongoing Phase 1b study.
- Cash and cash equivalents are approximately $46 million, providing a runway into 2029, excluding additional or expanded trials.
- No outstanding debt.
- The company is advancing its NDL2 (PD-L1 protein degrader) and MSETC (SETDB1 inhibitor) platforms toward IND-enabling studies.
- Paxalisib demonstrated a ~3.8 month improvement in median overall survival in newly diagnosed unmethylated glioblastoma patients in a prespecified secondary analysis.
Financial Impact
The $46 million cash position provides significant runway, reducing near-term financing risk. The positive clinical data could increase the company's valuation by enhancing the perceived probability of success for paxalisib.
Risk Factors
- The data presented is from a very small number of patients (n=3 evaluable), and the complete response was in an expanded access setting, not a controlled trial, so the results need to be confirmed in larger studies.
- The company's valuation is highly dependent on the success of its early-stage pipeline, which carries inherent clinical and regulatory risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-047770 |
| Document: ea0287737-6k_kazia.htm | 0001213900-26-047770 |
| Document: ea028773701ex99-2.htm | 0001213900-26-047770 |
| Document: 0001213900-26-047770-index-headers.html | 0001213900-26-047770 |
| Document: 0001213900-26-047770-index.html | 0001213900-26-047770 |
| Document: 0001213900-26-047770.txt | 0001213900-26-047770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.87 (−15.10%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.87 (−27.93%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.87 (−37.59%) |
Aug 31, 2026 7w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.87 (+37.69%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.87 (−42.85%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.87 (+42.05%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.87 (−42.05%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.87 (−37.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers